Abstract 4757
Background
In the U.S., most mCRPC patients will receive an ARSi (abiraterone, enzalutamide) in 1st line. More than 60% will receive a second, sequential ARSi (A-A) as opposed to ARSi then Taxane (A-T). No randomized studies exist comparing A-A and A-T. Recent real-world cohort risk-adjusted analyses were not able to discern differences in overall survival (OS) between A-A and A-T, despite a wide range of observed outcomes within groups. Using a cross-sectional cohort of standard of care in a tertiary center, we sought to determine if observations were consistent with community, and evaluate if nuclear AR-V7 could have additive effect on OS, specifically post-ARSi failure.
Methods
We previously reported utility of nuclear AR-V7 in two cross-sectional cohorts (Scher et al 2016 and Scher et al 2018). Blood was drawn from mCRPC patients prior to new line of therapy, AR-V7 testing by Epic Sciences, and therapy choice by physician without knowledge of AR-V7 status. OS data was updated, and a subset of these combined cohorts were analyzed (n = 148): those who had failed an ARSi, and were about to go onto a second ARSi (n = 73) or taxane (n = 75). A risk score was used to adjust for underlying patient imbalances and therapy choice propensity.
Results
75 of 148 (51%) received A-T and 73 of 148 (49%) received A-A. Adjusting for patient risk, a discernable difference in OS was not detected (HR: 1.16, CI: 0.73 – 1.85, p = 0.52). Incorporating AR-V7, there was a significant interaction between positivity for AR-V7 and OS on taxanes (HR: 0.16, CI: 0.052 – 0.52, p = 0.0020). In risk-matched analysis, there was a significant difference in OS between AR-V7(+) patients on taxanes vs. ARSi (11.6mo vs. 5.5mo, p = 0.0029).
Conclusions
Sequential ARSi use in the U.S. is common. Adjusting for patient risk and physician therapy choice, AR-V7 use after ARSi failure identifies patients who would live longer on taxanes vs. ARSi. Physician intuition alone was not sufficient to achieve predictive effect of AR-V7.
Clinical trial identification
Legal entity responsible for the study
MSKCC.
Funding
NIH/NCI P50-CA92629 SPORE in Prostate Cancer, NIH/NCI Cancer Center Support Grant P30-CA008748, NIH grant R01-CA207220, Department of Defense Prostate Cancer Research Program (PC121111 and PC131984), Prostate Cancer Foundation Challenge Award, and David H. Koch Fund for Prostate Cancer Research.
Editorial Acknowledgement
Disclosure
H.I. Scher: Consultant: Sanofi, Clovis, Janssen, Pfizer; Grant/research support to MSK: Innocrin, Janssen; Board of directors: Asterias Biotheraputics; Advisory board: WCG Oncology. R.P. Graf: Employee: Epic Sciences, Inc. R. Dittamore: Employee of Epic Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract